Conecte-se

Bibliografias temáticas / Anticancer drugs / Artigos de revistas

Siga este link para ver outros tipos de publicações sobre o tema: Anticancer drugs.

Artigos de revistas sobre o tema "Anticancer drugs"

Autor: Grafiati

Publicado: 4 de junho de 2021

Última modificação: 6 de setembro de 2023

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Anticancer drugs".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.

1

D, Subba Reddy, Prasanthi G, Amruth Raj S, Hari Krishna T, Sowjanya K e Shantha Kumari K. "EVALUATION OF ANTICANCER GENERIC DRUGS AND BRANDED DRUGS". Indian Research Journal of Pharmacy and Science 5, n.º 1 (março de 2018): 1378–91. http://dx.doi.org/10.21276/irjps.2018.5.1.16.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Reese, David M. "Anticancer drugs". Nature 378, n.º 6557 (dezembro de 1995): 532. http://dx.doi.org/10.1038/378532c0.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Kutty, Dr A. V. M. "Usefulness of Phytochemicals as Anticancer Drugs". JOURNAL OF CLINICAL AND BIOMEDICAL SCIENCES 16, n.º 1 (19 de março de 2019): 1–2. http://dx.doi.org/10.58739/jcbs/v09i1.7.

Texto completo da fonte

Resumo:

Cancer is a state of uncontrolled proliferation and dedifferentiation of cells in any tissues or organs of the body. The incidence of cancer is rising alarmingly and is one of the leading causes of morbidity and mortality globally. Normal cell division is precisely a planned biological process controlled by regulatory genes and specific metabolic pathways. Exposure of normally functioning cells to carcinogens leads to mutations in the genes causing loss of control of cell division and transform into cancerous. Over a period of time, these cancer cells acquire more mutations; invade to adjoining tissues, escape the process of apoptosis and the cells become eternal. Breakaway parts of the cancer tissues / cells travel through the lymphatic and blood vessels and get deposited in other tissues / organs leading to metastasis, the spread of cancer.

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Atkins, Joshua H., e Leland J. Gershell. "Selective anticancer drugs". Nature Reviews Drug Discovery 1, n.º 7 (julho de 2002): 491–92. http://dx.doi.org/10.1038/nrd842.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Atkins, Joshua H., e Leland J. Gershell. "Selective anticancer drugs". Nature Reviews Cancer 2, n.º 9 (setembro de 2002): 645–46. http://dx.doi.org/10.1038/nrc900.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Bibby, M. C. "Combretastatin anticancer drugs". Drugs of the Future 27, n.º 5 (2002): 475. http://dx.doi.org/10.1358/dof.2002.027.05.668645.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Meegan, Mary J., e Niamh M. O’Boyle. "Special Issue “Anticancer Drugs”". Pharmaceuticals 12, n.º 3 (16 de setembro de 2019): 134. http://dx.doi.org/10.3390/ph12030134.

Texto completo da fonte

Resumo:

The focus of this Special Issue of Pharmaceuticals is on the design, synthesis, and molecular mechanism of action of novel antitumor, drugs with a special emphasis on the relationship between the chemical structure and the biological activity of the molecules. This Special Issue also provides an understanding of the biologic and genotypic context in which targets are selected for oncology drug discovery, thus providing a rationalization for the biological activity of these drugs and guiding the design of more effective agents. In this Special Issue of Pharmaceuticals dedicated to anticancer drugs, we present a selection of preclinical research papers including both traditional chemotherapeutic agents and newer more targeted therapies and biological agents. We have included articles that report the design of small molecules with promising anticancer activity as tubulin inhibitors, vascular targeting agents, and topoisomerase targeting agents, alongside a comprehensive review of clinically successful antibody-drug conjugates used in cancer treatment.

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Ciarimboli, Giuliano. "Anticancer Platinum Drugs Update". Biomolecules 11, n.º 11 (4 de novembro de 2021): 1637. http://dx.doi.org/10.3390/biom11111637.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Zhang, Jason Y. "Apoptosis-based anticancer drugs". Nature Reviews Drug Discovery 1, n.º 2 (fevereiro de 2002): 101–2. http://dx.doi.org/10.1038/nrd742.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Blagosklonny, Mikhail V. "Teratogens as Anticancer Drugs". Cell Cycle 4, n.º 11 (22 de agosto de 2005): 1518–21. http://dx.doi.org/10.4161/cc.4.11.2208.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

KOPEČEK, JINDŘICH. "Targetable Polymeric Anticancer Drugs." Annals of the New York Academy of Sciences 618, n.º 1 Temporal Cont (fevereiro de 1991): 335–44. http://dx.doi.org/10.1111/j.1749-6632.1991.tb27253.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Mundy, Gregory R., e Toshiyuki Yoneda. "Bisphosphonates as Anticancer Drugs". New England Journal of Medicine 339, n.º 6 (6 de agosto de 1998): 398–400. http://dx.doi.org/10.1056/nejm199808063390609.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Miyamoto, Shingo, Manabu Yamada, Yasuyo Kasai, Akito Miyauchi e Kazumichi Andoh. "Anticancer drugs during pregnancy". Japanese Journal of Clinical Oncology 46, n.º 9 (9 de junho de 2016): 795–804. http://dx.doi.org/10.1093/jjco/hyw073.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

Xing, Z., D. Li, L. Yang, Y. Xi e X. Su. "MicroRNAs and anticancer drugs". Acta Biochimica et Biophysica Sinica 46, n.º 3 (3 de fevereiro de 2014): 233–39. http://dx.doi.org/10.1093/abbs/gmu003.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

Wallis, Denise, James Claffey, Brendan Gleeson, Megan Hogan, Helge Müller-Bunz e Matthias Tacke. "Novel zirconocene anticancer drugs?" Journal of Organometallic Chemistry 694, n.º 6 (março de 2009): 828–33. http://dx.doi.org/10.1016/j.jorganchem.2008.08.020.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

Bradley, David. "Self-assembling anticancer drugs". Materials Today 41 (dezembro de 2020): 3. http://dx.doi.org/10.1016/j.mattod.2020.10.015.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

Russell, Stephen J., e Kah-Whye Peng. "Viruses as anticancer drugs". Trends in Pharmacological Sciences 28, n.º 7 (julho de 2007): 326–33. http://dx.doi.org/10.1016/j.tips.2007.05.005.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Kerwin, Sean. "Toward Bioengineering Anticancer Drugs". Chemistry & Biology 9, n.º 9 (setembro de 2002): 956–58. http://dx.doi.org/10.1016/s1074-5521(02)00222-3.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Rohr, Jürgen. "Cryptophycin Anticancer Drugs Revisited". ACS Chemical Biology 1, n.º 12 (dezembro de 2006): 747–50. http://dx.doi.org/10.1021/cb6004678.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

Denny, William A. "Hypoxia-activated anticancer drugs". Expert Opinion on Therapeutic Patents 15, n.º 6 (junho de 2005): 635–46. http://dx.doi.org/10.1517/13543776.15.6.635.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

Bordon, Yvonne. "Anticancer drugs copy bugs". Nature Reviews Cancer 14, n.º 12 (24 de novembro de 2014): 767. http://dx.doi.org/10.1038/nrc3866.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

Van der Veldt, Astrid A. M., Adriaan A. Lammertsma e Egbert F. Smit. "Scheduling of anticancer drugs". Cell Cycle 11, n.º 23 (dezembro de 2012): 4339–43. http://dx.doi.org/10.4161/cc.22187.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

Mundy, Gregory R. "Bisphosphonates as anticancer drugs". Expert Opinion on Investigational Drugs 8, n.º 12 (dezembro de 1999): 2009–15. http://dx.doi.org/10.1517/13543784.8.12.2009.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

Bordon, Yvonne. "Anticancer drugs need bugs". Nature Reviews Immunology 14, n.º 1 (13 de dezembro de 2013): 1. http://dx.doi.org/10.1038/nri3591.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

Bordon, Yvonne. "Anticancer drugs copy bugs". Nature Reviews Immunology 14, n.º 12 (14 de novembro de 2014): 776–77. http://dx.doi.org/10.1038/nri3775.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

26

Jefford, Michael, Linda Mileshkin, Penelope Schofield, Emilia Agalianos, Jacqui Thomson e John Zalcberg. "Discussing Expensive Anticancer Drugs". Journal of Clinical Oncology 27, n.º 3 (20 de janeiro de 2009): 476–77. http://dx.doi.org/10.1200/jco.2008.20.1780.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

27

Schwartsmann, G. "Anticancer drugs from nature". Medical and Pediatric Oncology 37, n.º 1 (2001): 79–80. http://dx.doi.org/10.1002/mpo.1173.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

28

Janus, Nicolas. "Gastrointestinal Disorders and Toxicities Induced By Anticancer Drugs. Another Risk Factor of Bleeding in Cancer-Associated Thrombosis". Blood 136, Supplement 1 (5 de novembro de 2020): 36. http://dx.doi.org/10.1182/blood-2020-141814.

Texto completo da fonte

Resumo:

Introduction Anticancer treatments has been changing since decades, evolving from chemotherapy (platinum salts) to recent check-point inhibitors. Nausea, vomiting and diarrhoea are common adverse events of anticancer drugs, despites the fact that some supportive care drugs can manage these adverse events. Gastro-intestinal (GI) disorders/toxicities are also important. Such as gastric/duodenal ulcer, gastritis, stomatitis, colitis, esophagitis... Cancer-associated-thrombosis (CAT) patients were also reported to be exposed to such GI disorders/toxicities and several publications recommended to consider these GI disorders/toxicities when choosing an anticoagulant in CAT (Carrier M. Curr Oncol 2018; Moik F. ESMO Open 2020). However, little is known about the nature of the anticancer drugs that CAT patients are receiving. The aim of this work was to check all the anticancer's SmPCs (Summary of Product Characteristics) on the EMA website for GI disorders. Methods All SmPCs of anticancer drugs indicated for lung cancer were checked on the EMA website. All adverse events regarding GI disorders/toxicities were collected. The frequency of adverse events used was the following: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1000); very rare (< 1/10,000). However, it was decided to mainly focus on very common and common ones. Old anticancer drugs SmPCs (platinium salts...) were checked on electronic medicines compendium (medicines.org.uk), because these old SmPCs are not always available on the EMA website. Generics, biosimilars and drugs without a licence were excluded. Results Twenty-eight anticancer drugs were identified with a mix of traditional chemotherapies (platinum salts...), tyrosine kinase inhibitors (nib) and monoclonal antibodies (mab). Among these 28 anticancer drugs, 26 had at least one very common/common GI disorders/toxicities. Obviously, vomiting (82.1%) and diarrhoea (89.3%) are very well-known, but it was interesting to see that many anticancer drugs were associated with other very common/common GI toxicities such as stomatitis (71.4%) and colitis (10.7%). Additionally, several drugs (35.7%) were exposing to GI bleeding and/or GI perforation but these last adverse events were less common. Unfortunately, the SmPCs did not include data about the GI profile of the patients during the trials. Conclusion Monreal M et al reported in 1991 that acute gastroduodenal lesion was found in 21% of patients with venous thromboembolism, but there are no dedicated study about the incidence of GI disorders in CAT patients. This work reported that GI disorders/toxicities were common in anticancer drug's SmPCs. Consequently, it is important to be aware of this before initiating an anticoagulant treatment. However, this work had limitations. Indeed, these adverse events were reported in the SmPCs, based mainly on cancer trials and not on CAT trials. Furthermore, clinical trials and SmPCs may not always reflect the real clinical setting. Finally, lung cancer patients are usually receiving anticancer regimens that include several anticancer drugs, so the potential impact of GI disorders/toxicities from 2 or 3 anticancer drugs on a single patients could be greater. Nevertheless, it sounds reasonable to check for GI disorders/toxicities risks in order to initiate an adequate anticoagulant treatment in CAT patients and during follow-up. Disclosures Janus: Guerbet:Research Funding;B-Braun:Honoraria;LEO Pharma A/S:Current Employment, Honoraria;Fresenius Medical Care:Honoraria;Amgen:Honoraria, Research Funding;TEVA:Research Funding;Daichii-Sankyo:Honoraria, Research Funding;Roche:Honoraria, Research Funding;Vifor Pharma:Honoraria, Research Funding;Gilead:Honoraria, Research Funding;Novartis:Honoraria;Pierre Fabre Oncology:Research Funding;Bayer:Honoraria, Research Funding;Pfizer:Consultancy, Honoraria;IPSEN:Honoraria.

Estilos ABNT, Harvard, Vancouver, APA, etc.

29

Li, Dong Hong, Jun Lin Diao, Ke Gui Yu e Cheng He Zhou. "Synthesis and anticancer activities of porphyrin induced anticancer drugs". Chinese Chemical Letters 18, n.º 11 (novembro de 2007): 1331–34. http://dx.doi.org/10.1016/j.cclet.2007.09.012.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

30

&NA;. "Anticancer drugs from the sea". Inpharma Weekly &NA;, n.º 1417 (dezembro de 2003): 4. http://dx.doi.org/10.2165/00128413-200314170-00007.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

31

Evans, William E., e Mary V. Relling. "Clinical Pharmacokinetics-Pharmacodynamicsof Anticancer Drugs". Clinical Pharmacokinetics 16, n.º 6 (junho de 1989): 327–36. http://dx.doi.org/10.2165/00003088-198916060-00001.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

32

Carcone, Bernard, e Dionyssis Pongas. "Cardiovascular toxicity of anticancer drugs". Sang thrombose vaisseaux 26, n.º 4 (julho de 2014): 188–96. http://dx.doi.org/10.1684/stv.2014.0849.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

33

Amelio, Ivano, Andrey Lisitsa, Richard Knight, Gerry Melino e Alexey Antonov. "Polypharmacology of Approved Anticancer Drugs". Current Drug Targets 18, n.º 5 (24 de fevereiro de 2017): 534–43. http://dx.doi.org/10.2174/1389450117666160301095233.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

34

Jeanny B. Aragon-Ching, Haiqing Li, Erin R. Gardner e William D. Figg. "Thalidomide Analogues as Anticancer Drugs". Recent Patents on Anti-Cancer Drug Discovery 2, n.º 2 (1 de junho de 2007): 167–74. http://dx.doi.org/10.2174/157489207780832478.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

35

Meegan, Mary J., e Niamh M. O’Boyle. "Special Issue “Anticancer Drugs 2021”". Pharmaceuticals 15, n.º 4 (14 de abril de 2022): 479. http://dx.doi.org/10.3390/ph15040479.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

36

Benjamin Garbutcheon-Singh, K., Maxine P. Grant, Benjamin W. Harper, Anwen M. Krause-Heuer, Madhura Manohar, Nikita Orkey e Janice R. Aldrich-Wright. "Transition Metal Based Anticancer Drugs". Current Topics in Medicinal Chemistry 11, n.º 5 (1 de março de 2011): 521–42. http://dx.doi.org/10.2174/156802611794785226.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

37

Fujita, Ken-ichi. "Cytochrome P450 and Anticancer Drugs". Current Drug Metabolism 7, n.º 1 (1 de janeiro de 2006): 23–37. http://dx.doi.org/10.2174/138920006774832587.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

38

Wallace, H. M., e A. V. Fraser. "Polyamine analogues as anticancer drugs". Biochemical Society Transactions 31, n.º 2 (1 de abril de 2003): 393–96. http://dx.doi.org/10.1042/bst0310393.

Texto completo da fonte

Resumo:

Just over 30 years ago, the late Diane Russell published the first in a series of papers linking polyamines and cancer. These early studies led to a flurry of research activity in the polyamine field that continues to this day attempting to identify a role for the polyamines in cancer development, treatment and/or prevention. The recognition that polyamines are critical for the growth of cancer cells, and consequently the identification of their metabolic pathways as a target for therapeutic intervention, led to the development of a number of useful inhibitors of polyamine biosynthesis. Arguably the most significant addition to the polyamine field in the last 30 years was the synthesis of α-difluoromethylornithine (DFMO), which is being tested currently as a cancer chemopreventative agent in man and is used also as a highly effective trypanocidal agent. Although an extremely useful tool experimentally, DFMO has been disappointing in clinical trials with little therapeutic efficacy. Despite this setback, the polyamine pathway is still considered a viable target for chemotherapeutic intervention. This has led to the development of the polyamine analogues as multifunctional inhibitors that will produce inhibition of tumour cell growth, polyamine depletion and optimum therapeutic efficacy.

Estilos ABNT, Harvard, Vancouver, APA, etc.

39

Hyodo, Kenji, Eiichi Yamamoto, Takuya Suzuki, Hiroshi Kikuchi, Makoto Asano e Hiroshi Ishihara. "Development of Liposomal Anticancer Drugs". Biological and Pharmaceutical Bulletin 36, n.º 5 (2013): 703–7. http://dx.doi.org/10.1248/bpb.b12-01106.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

40

Powis, Garth, Miles P. Hacker e Graziano C. Carlon. "The Toxicity of Anticancer Drugs". Critical Care Medicine 21, n.º 7 (julho de 1993): 1101. http://dx.doi.org/10.1097/00003246-199307000-00034.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

41

Baumann, F., e R. Preiss. "Cyclophosphamide and related anticancer drugs". Journal of Chromatography B: Biomedical Sciences and Applications 764, n.º 1-2 (novembro de 2001): 173–92. http://dx.doi.org/10.1016/s0378-4347(01)00279-1.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

42

Tjaden, U. R., e E. A. De Bruijn. "Chromatographic analysis of anticancer drugs". Journal of Chromatography B: Biomedical Sciences and Applications 531 (outubro de 1990): 235–94. http://dx.doi.org/10.1016/s0378-4347(00)82286-0.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

43

Sapra, P., e T. M. Allen. "Ligand-targeted liposomal anticancer drugs". Progress in Lipid Research 42, n.º 5 (setembro de 2003): 439–62. http://dx.doi.org/10.1016/s0163-7827(03)00032-8.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

44

Tanigawara, Y. "Pharmaco-Metabolomics for Anticancer Drugs". Annals of Oncology 23 (outubro de 2012): xi55. http://dx.doi.org/10.1016/s0923-7534(20)32076-7.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

45

Yoshioka, T. "Drugs Interaction of Anticancer Agents". Annals of Oncology 23 (outubro de 2012): xi65. http://dx.doi.org/10.1016/s0923-7534(20)32111-6.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

46

Muers, Mary. "Transgenerational effects of anticancer drugs". Nature Reviews Genetics 13, n.º 3 (14 de fevereiro de 2012): 148. http://dx.doi.org/10.1038/nrg3190.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

47

Gosland, Michael P., e Bert L. Lum. "The Anticancer Drugs, 2nd Edition". Annals of Pharmacotherapy 29, n.º 3 (março de 1995): 320. http://dx.doi.org/10.1177/106002809502900321.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

48

Meyer, G. "Pulmonary Toxicity of Anticancer Drugs". Annals of Oncology 25 (setembro de 2014): iv33. http://dx.doi.org/10.1093/annonc/mdu310.2.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

49

Imran, Muhammad, Wagma Ayub, Ian S. Butler e Zia-ur-Rehman. "Photoactivated platinum-based anticancer drugs". Coordination Chemistry Reviews 376 (dezembro de 2018): 405–29. http://dx.doi.org/10.1016/j.ccr.2018.08.009.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

50

SALVIK, MILAN, JUN WU e CHRISTOPHER RILEY. "Salivary Excretion of Anticancer Drugs". Annals of the New York Academy of Sciences 694, n.º 1 Saliva as a D (setembro de 1993): 319–21. http://dx.doi.org/10.1111/j.1749-6632.1993.tb18377.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!